Structural Divergence of In Vitro and In Vivo Protein Aggregates

35 concepts19 papers

For decades, the standard blueprint for studying neurodegenerative diseases in the laboratory seemed straightforward: take a purified recombinant protein—such as tau or $\alpha$-synuclein—shake it in a test tube with an anionic inducer like heparin, and use the resulting synthetic fibrils to model the pathology of human brains.

However, the advent of high-resolution cryo-electron microscopy (cryo-EM) has shattered this paradigm. When researchers began solving the atomic structures of filaments extracted directly from patient tissues, they discovered something unsettling: lab-grown filaments look fundamentally different from those found in human patients. Synthetic aggregates often form entirely different "folds," exhibit high structural randomness (polymorphism), and fail to replicate the precise molecular architecture of actual disease strains.

Understanding why this structural gap exists—and why standard laboratory models fail to replicate physiological aggregation—is one of the most critical challenges in modern translational neuroscience.

The Failure of De Novo Assembly

To understand why synthetic aggregation fails, we must look at the thermodynamic landscape of protein misfolding. A disordered protein monomer does not have a single path to an aggregated state; instead, it faces a complex energy landscape with many deep local minima.

In a living human brain, the cellular environment guides a protein down a highly specific path, resulting in a uniform, disease-specific fold. In contrast, standard in vitro environments lack these cellular constraints. When researchers attempt to force purified proteins to aggregate in a test tube, the proteins drop into alternative thermodynamic traps.

[Disordered Monomer] 
       │
       ├─► (In Vitro + Heparin) ──► Polymorphic, non-pathological folds
       │
       └─► (In Vivo Cellular Context) ──► Uniform, disease-specific folds (e.g., Alzheimer's fold)

Wenjuan Zhang et al. demonstrated this limitation in Heparin-induced tau filaments are polymorphic and differ from those in Alzheimer’s and Pick’s diseases. They showed that when tau is assembled in vitro using heparin, it forms a highly polymorphic mixture of filaments that completely lack the structural signatures of filaments extracted from Alzheimer's or Pick's disease brains.

As reviewed by Michel Goedert et al. in Tau and neurodegeneration, relying on artificial, negatively charged substances to force recombinant tau into filaments fails to capture the natural mechanisms of filament formation. Without the native cellular environment, the resulting structures are little more than laboratory artifacts.

Why Seeded Amplification Drifts

If building filaments from scratch (de novo) yields the wrong structures, a logical alternative is seeded assembly. In this approach, a tiny amount of a patient's brain aggregate is used as a physical "seed" to template the folding of recombinant monomers in a test tube or a cell culture model. The seed is supposed to act as a mold, forcing the incoming monomers to adopt its exact shape.

Remarkably, cryo-EM reveals that even this templating process frequently breaks down. As recombinant monomers attach to the ends of a native seed in vitro, the structural information contained in the seed can drift.

Sofia Lövestam et al. exposed this limitation in Seeded assembly in vitro does not replicate the structures of α‐synuclein filaments from multiple system atrophy. They found that when recombinant $\alpha$-synuclein monomers were elongated using native seeds from Multiple System Atrophy (MSA) brains, the resulting in vitro filaments failed to replicate the native MSA filament structures. The structural fidelity was lost during amplification because the test tube environment lacked the necessary stabilizing factors present in the human brain.

This structural drift occurs even within simplified cellular models. When Airi Tarutani et al. seeded cultured human SH-SY5Y cells with tau aggregates from Alzheimer's disease or corticobasal degeneration brains (<scp>Cryo‐EM</scp> structures of tau filaments from <scp>SH‐SY5Y</scp> cells seeded with brain extracts from cases of Alzheimer's disease and corticobasal degeneration), the newly formed filaments only partially resembled the original brain-derived seeds. The cellular environment of a simplified cell line is still too far removed from the complex environment of a degenerating human brain to maintain perfect structural replication.

The Missing Ingredients: PTMs and Co-Factors

Why does the structure drift during in vitro amplification? The answer lies in two factors that are missing from standard laboratory preparations: post-translational modifications (PTMs) and non-proteinaceous co-factors.

Pathological filaments are rarely composed of pure, unaltered protein sequences. In a diseased brain, proteins undergo extensive chemical modifications—such as phosphorylation, ubiquitination, and acetylation—and are tightly packed alongside cellular co-factors like lipids or nucleic acids. These modifications alter the local electrostatic charges and steric boundaries of the protein, locking it into a specific pathological fold.

Native Filament Core = Recombinant Sequence + Specific PTM Patterns + Cellular Co-factors
                                                    │
                                                    ▼
                                      (Locks the pathological fold)

Alysa Kasen et al. highlighted this interplay in Driving Tau Pathogenicity Seeding ‐ How Fibril Structure and Post‐Translational Modifications Alter Seeding Capacity. They demonstrated that even when recombinant tau fibrils are engineered to mimic the geometric core of Alzheimer's filaments, they fail to replicate the pathological seeding capacity of native patient fibrils unless they also capture the complex PTM patterns found in vivo.

The native cellular environment dictates which folds are physically possible. For example, Yang Yang et al. solved the atomic structures of $\alpha$-synuclein filaments from Lewy pathology (Structures of α-synuclein filaments from human brains with Lewy pathology), revealing a distinct "Lewy fold" that is structurally separate from the folds seen in other synucleinopathies like MSA.

When researchers attempt to replicate these patient-derived structures using standard in vitro methods, the absence of the native cellular environment causes the assembly process to fail. In another study by Yang Yang et al. (New SNCA mutation and structures of α-synuclein filaments from juvenile-onset synucleinopathy), standard in vitro assembly methods completely failed to reproduce the unique, patient-specific $\alpha$-synuclein filament structure observed in a case of juvenile-onset synucleinopathy.

The Translational Consequences

This structural divergence is not just an academic problem; it has severe consequences for the development of diagnostics and therapeutics. If a pharmaceutical company designs a small molecule or an antibody to bind to a synthetic, lab-grown protein aggregate, that drug will likely fail in clinical trials if the actual aggregate in the patient's brain has a completely different atomic fold.

This issue is particularly clear in diagnostic development. The authors of An antibody scanning method for the detection of α-synuclein oligomers in the serum of Parkinson's disease patients noted that protein aggregates formed within the complex environment of human biofluids possess distinct structural features compared to those generated under controlled laboratory conditions. Consequently, diagnostic tools trained exclusively on synthetic laboratory fibrils often fail to recognize or characterize the natural, pathologically relevant aggregates present in patient serum.

This gap between synthetic environments and biological reality appears across many areas of aggregation research:

Bridging the Gap

To overcome these limitations, researchers are developing more sophisticated in vitro amplification methods that respect the structural constraints of native tissue.

Hong Xu et al. demonstrated in In vitro amplification of pathogenic tau conserves disease-specific bioactive characteristics that by carefully optimizing amplification conditions, patient-derived tau seeds can template recombinant tau while conserving the disease-specific biological "fingerprints" of Alzheimer's disease, corticobasal degeneration, and progressive supranuclear palsy.

Similarly, Alessia Santambrogio et al. showed in Serial amplification of tau filaments using Alzheimer's brain homogenates and <scp>C322A</scp> or <scp>C322S</scp> recombinant tau that introducing specific mutations (such as C322A or C322S) into recombinant tau can alter its structural flexibility. This modification helps the protein overcome the typical in vitro thermodynamic traps, allowing it to adopt configurations that closer resemble native Alzheimer's disease filaments during real-time quaking-induced conversion (RT-QuIC) assays.

Ultimately, the field is moving away from simple, artificial aggregation models. By recognizing that pathological protein folds are a product of both the protein sequence and its specific cellular environment, researchers are building high-fidelity models that better reflect actual human disease.

Key Foundational Work

Heparin-induced tau filaments are polymorphic and differ from those in Alzheimer’s and Pick’s diseases (2019) — contributed 3 concept elements to this direction.
The Movement Protein of Tomato Mosaic Tobamovirus Induces Tubular Structures in Tomato Protoplasts. (1999) — contributed 1 concept elements to this direction.
History & citationVersion 1 · 2026-10-04

Current · Permanent link

View frozen version 1

Cite this direction

Latest version (a living page):

@misc{lacuna_prion_strain_replication_limitations_179575fa,
  title = {prion strain replication limitations},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/prion-strain-replication-limitations/rdr_179575fa1e44407ba3377816498a3448},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-20},
}

This exact version (version 1, frozen text):

@misc{lacuna_prion_strain_replication_limitations_179575fa_v1,
  title = {prion strain replication limitations},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/prion-strain-replication-limitations/rdr_179575fa1e44407ba3377816498a3448/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-20},
}

See something wrong? Report a mistake